Evidence map›Paper›PMID 27347038›Full record

ArticleExperimental and therapeutic medicine2016

Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNβ-treated and untreated multiple sclerosis patients.

Refik Pul, Mehdi Saadat, Franco Morbiducci, Thomas Skripuletz, Ünsal Pul, Dorothee Brockmann, Kurt-Wolfram Sühs, Philipp Schwenkenbecher, Kai Günter Kahl, Kaweh Pars and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Defining Disease Activity and Response to Therapy in MS.Current treatment options in neurology · 2017
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Refik PulDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Mehdi SaadatDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Franco MorbiducciDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Thomas SkripuletzDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Ünsal PulDepartment of Thoracic and Cardiovascular Surgery, University Hospital Essen, 45147 Essen, Germany.
Dorothee BrockmannDepartment of Ophthalmology, Hannover Medical School, 30625 Hannover, Germany.
Kurt-Wolfram SühsDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Philipp SchwenkenbecherDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Kai Günter KahlDepartment of Psychiatry, Hannover Medical School, 30625 Hannover, Germany.
Kaweh ParsDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Martin StangelDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Corinna TrebstDepartment of Neurology, Hannover Medical School, 30625 Hannover, Germany.
Medizinische Hochschule Hannover · DEEssen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantification of the retinal nerve fiber layer (RNFL) by optical coherence tomography (OCT) has been proposed to provide an indirect measure for retinal axonal loss. The aim of the present study was to determine whether interferon beta (IFNβ) treatment impedes retinal axonal loss in multiple sclerosis (MS) patients. A total of 48 patients with MS (24 IFNβ-1b-treated and 24 untreated subjects) and 12 healthy controls were enrolled in a prospective longitudinal OCT study. OCT measurements were performed for both eyes of each subject at baseline, and at 3-, 6-, and 12-month follow-up examinations using a time-domain OCT. At each visit, we additionally recorded full-field visual evoked potential (VEP) responses and performed the paced auditory serial addition test (PASAT), in addition to expanded disability status scale (EDSS) scoring. Generalized estimation equation (GEE) was used to account for repeated measurements and paired-data. The model-based approach predicted a monthly reduction in the RNFL thickness by 0.19 µm in the eyes of the MS subjects. The reduction was estimated to be 0.17 µm in case of IFNβ-treatment and 0.16 µm in case of no treatment. Treatment duration and group allocation were not significantly associated with the RNFL thickness. Inclusion of further longitudinal data (EDSS, two and three second PASAT) in each of our models did not result in any significant association. In summary, over a period of one year no significant association between IFNβ-1b treatment and RNFL thinning was identified in patients with MS.

Indexed as

interferon β-1blongitudinal studymultiple sclerosisoptical coherence tomographyretinal nerve fiber layer thickness

Identifiers

PMID27347038
PMCPMC4906774
OpenAlexW2343000825

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.